in combination with other drugs enrollment paused SOURCE: Company disclosures, clinicaltrials.gov
In multiple myeloma, many companies are taking aim at a disease-specific protein called BCMA, following the same approach of the approved drugs Blenrep from GlaxoSmithKline and Abecma from Bristol Myers Squibb. In leukemia and lymphoma, the target protein on the tumor cells is called CD20, to which the aging Roche drug Rituxan also binds.
Roche is the most advanced using the CD20/CD3 approach, with two drugs called mosunetuzumab and glofitamab in Phase 3 trials. The former is being tested in combination with Bristol Myers Revlimid against a Rituxan-Revlimid combination in follicular lymphoma, while the latter is being combined with a chemotherapy combination in a trial that compares it to Rituxan and chemo in diffuse large B cell lymphoma.